United States - English - NLM (National Library of Medicine)

h3 medical inc - tegaserod maleate (unii: e5xnt3rf5a) (tegaserod - unii:458vc51857) -

United States - English - NLM (National Library of Medicine)

us worldmeds, llc - tegaserod (unii: 458vc51857) (tegaserod - unii:458vc51857) - zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (ibs-c). limitations of use - the safety and effectiveness of zelnorm in men with ibs-c have not been established [see clinical studies (14)] . zelnorm is contraindicated in patients with: - a history of myocardial infarction (mi), stroke, transient ischemic attack (tia), or angina [see warnings and precautions (5.1)] - a history of ischemic colitis or other forms of intestinal ischemia [see warnings and precautions (5.2)] - severe renal impairment (egfr< 15 ml/min/1.73 m2 ) or end-stage renal disease [see use in specific populations (8.6)] - moderate and severe hepatic impairment (child-pugh b or c) [see use in specific populations (8.7)] - a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions [see adverse reactions (6.2)] - hypersensitivity to tegaserod [see adverse reactions (6.2)] risk summary availabl

United States - English - NLM (National Library of Medicine)

alfasigma usa, inc. - tegaserod (unii: 458vc51857) (tegaserod - unii:458vc51857) - zelnorm is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (ibs-c). limitations of use - the safety and effectiveness of zelnorm in men with ibs-c have not been established [see clinical studies ( 14 )] . zelnorm is contraindicated in patients with: - a history of myocardial infarction (mi), stroke, transient ischemic attack (tia), or angina [see warnings and precautions ( 5.1 )] - a history of ischemic colitis or other forms of intestinal ischemia [see warnings and precautions ( 5.2 )] - severe renal impairment (egfr< 15 ml/min/1.73 m2 ) or end-stage renal disease [see use in specific populations ( 8.6 )] - moderate and severe hepatic impairment (child-pugh b or c) [see use in specific populations ( 8.7 )] - a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of oddi dysfunction, or abdominal adhesions [see adverse reactions ( 6.2 )] - hypersensitivity to tegaserod [see adverse reactions ( 6.2 )] risk summar

United States - English - NLM (National Library of Medicine)

bluebay shandong co.,ltd - tegaserod maleate (unii: e5xnt3rf5a) (tegaserod maleate - unii:e5xnt3rf5a) -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - tegaserod maleate 8.31mg equivalent to 6 mg tegaserod; tegaserod maleate 8.31mg equivalent to 6 mg tegaserod - tablet - 6 mg - active: tegaserod maleate 8.31mg equivalent to 6 mg tegaserod excipient: crospovidone glycerol hypromellose lactose monohydrate macrogol 4000 poloxamer 188 water active: tegaserod maleate 8.31mg equivalent to 6 mg tegaserod excipient: colloidal silicon dioxide crospovidone glyceryl behenate hypromellose lactose monohydrate

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - tegaserod - irritable bowel syndrome - drugs for functional gastrointestinal disorders - zelnorm is indicated for the repeated symptomatic short-term treatment of women with irritable bowel syndrome (ibs) whose predominant bowel habit is constipation, associated with abdominal pain/discomfort or bloating (see section 4.2).

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - tegaserod - tablet - 6 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.125 mg - digoxin is indicated for the treatment of mild to moderate heart failure in adults. digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ace) inhibitor. digoxin increases myocardial contractility in pediatric patients with heart failure. digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation. digoxin is contraindicated in patients with: - ventricular fibrillation [see warnings and precautions (5.1)] - known hypersensitivity to digoxin (reactions seen include unexplained rash, swelling of the mouth, lips or throat or a difficulty in breathing). a hypersensitivity reaction to other digitalis preparations usually constitutes a contraindication to digoxin. digo

United States - English - NLM (National Library of Medicine)

precision dose, inc. - digoxin (unii: 73k4184t59) (digoxin - unii:73k4184t59) - digoxin 0.05 mg in 1 ml